BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 6362851)

  • 1. Dipyridamole enhancement of toxicity to L1210 cells by deoxyadenosine and deoxycoformycin combinations in vitro.
    Kang GJ; Kimball AP
    Cancer Res; 1984 Feb; 44(2):461-6. PubMed ID: 6362851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2'-deoxycoformycin and deoxyadenosine in vitro.
    Begleiter A; Pugh L; Israels LG; Johnston JB
    Cancer Res; 1988 Jul; 48(14):3981-6. PubMed ID: 3260129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deoxycoformycin-induced response in chronic lymphocytic leukaemia: deoxyadenosine toxicity in non-replicating lymphocytes.
    Kefford RF; Fox RM
    Br J Haematol; 1982 Apr; 50(4):627-36. PubMed ID: 6978147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of nucleoside transport inhibitors on the salvage and toxicity of adenosine and deoxyadenosine in L1210 and P388 mouse leukemia cells.
    Plagemann PG; Wohlhueter RM
    Cancer Res; 1985 Dec; 45(12 Pt 1):6418-24. PubMed ID: 3877568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
    Yu AL; Bakay B; Kung FH; Nyhan WL
    Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of DNA strand breaks in chronic lymphocytic leukemia following treatment with 2'-deoxycoformycin in vivo and in vitro.
    Begleiter A; Glazer RI; Israels LG; Pugh L; Johnston JB
    Cancer Res; 1987 May; 47(9):2498-503. PubMed ID: 3494509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects on cultured L1210 leukemia cells of the ribosyl, 2'-deoxyribosyl, and xylosyl homologs of tubercidin and adenosine alone or in combination with 2'-deoxycoformycin.
    Cass CE; Selner M; Tan TH; Muhs WH; Robins MJ
    Cancer Treat Rep; 1982 Feb; 66(2):317-26. PubMed ID: 6976834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of multiple myeloma with deoxycoformycin.
    Belch AR; Henderson JF; Brox LW
    Cancer Chemother Pharmacol; 1985; 14(1):49-52. PubMed ID: 3871175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential sensitivity of leukemic cells to growth inhibition by deoxyadenosine and deoxycoformycin.
    Tanaka M; Kimura K
    Tohoku J Exp Med; 1985 Dec; 147(4):331-41. PubMed ID: 3879563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
    Paine RM; Weston BJ; Clink HM; Kohn J; Neville AM; McGhee KG; Harrap KR
    Cancer Treat Rep; 1981; 65(3-4):259-66. PubMed ID: 6972254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of RNA synthesis by deoxyadenosine plus deoxycoformycin in resting lymphocytes.
    Matsumoto SS; Yu J; Yu AL
    J Immunol; 1983 Dec; 131(6):2762-6. PubMed ID: 6196398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic effect of 3'-deoxyadenosine N1-oxide and adenosine deaminase inhibitors on growth of Ehrlich ascites tumor cells in vivo.
    Svendsen KR; Overgaard-Hansen K; Frederiksen S
    Cancer Chemother Pharmacol; 1988; 21(1):35-9. PubMed ID: 3257721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deoxyadenosine triphosphate accumulation in erythrocytes of deoxycoformycin-treated mice.
    Smith CM; Henderson JF
    Biochem Pharmacol; 1982 Apr; 31(8):1545-51. PubMed ID: 6980005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the biochemical sequelae of therapy in Thy-acute lymphoblastic leukaemia with the adenosine deaminase inhibitor 2' deoxycoformycin.
    Russell NH; Prentice HG; Lee N; Piga A; Ganeshaguru K; Smyth JF; Hoffbrand AV
    Br J Haematol; 1981 Sep; 49(1):1-9. PubMed ID: 6974003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular responses in mouse leukemia L1210 cells made resistant to deoxyadenosine.
    Cory AH; Cory JG
    Biochem Biophys Res Commun; 1998 Aug; 249(3):687-91. PubMed ID: 9731198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA strand breaks induced in human T-lymphocytes by the combination of deoxyadenosine and deoxycoformycin.
    Brox L; Ng A; Pollock E; Belch A
    Cancer Res; 1984 Mar; 44(3):934-7. PubMed ID: 6607110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP depletion as a consequence of adenosine deaminase inhibition in man.
    Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
    Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphological changes in leukemic lymphoblasts and normal lymphocytes treated with deoxyadenosine plus deoxycoformycin.
    Matsumoto SS; Yu AL; Yu J
    Cancer Invest; 1985; 3(3):225-33. PubMed ID: 3873981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine.
    Plunkett W; Benjamin RS; Keating MJ; Freireich EJ
    Cancer Res; 1982 May; 42(5):2092-6. PubMed ID: 6175407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.